Flatiron’s integrated real-world evidence solutions transform the possibilities of oncology research, development, and commercialization. Whether you're tackling bold research questions or time-critical decision points along the way, our solutions deliver the data, tools, and support you need to achieve your goals faster and more efficiently than ever before.
Solutions across the oncology product lifecycle
Flatiron’s tailored real-world evidence solutions can shorten timelines, minimize risks associated with drug development, and support access to the therapies that patients need. That’s why the world’s top life sciences companies rely on our solutions across the drug lifecycle, from research and development to in-market strategies.
Pioneering real-world data paired with the top real-world evidence experts
Flatiron employs a world-class oncology team, including clinical and research oncologists, biostatisticians, epidemiologists, and health outcomes researchers. With their dedication to high-quality real-world evidence, our real-world data is recognized as the best option for creating insights and evidence that power the future of cancer care.
From the point of care to insights and evidence
At Flatiron, we are integrated at the source. With our technology and electronic health record systems used in thousands of community oncology and academic centers nationwide, we provide access to the point of care data with traceability to source documents.
But our commitment to data quality doesn't stop there. Our team of clinicians and data experts employ innovative and rigorous curation methods, including machine learning and data abstraction, to ensure the highest quality standards at the scale you require.
By the numbers
Patient records de-identified and available for research
Peer-reviewed publications using Flatiron’s real-world data, including over 60 in top-tier journals
Unique sites of care. Patients represented: ~75% community clinics and ~25% academic medical centers
Real-world oncology experts including biostatisticians, epidemiologists, health outcomes researchers, and oncologists many of whom still practice in clinic
High-quality oncology disease-specific Enhanced Datamarts
Years exclusively focused on oncology, founded in 2012—Flatiron has redefined real-world evidence in oncology
The building blocks of our real-world evidence solutions
Flatiron uses innovative approaches like data abstraction and machine learning methods to optimize data curation. By linking data at the patient-level from different sources, we’re able to integrate RWD from electronic health records (EHR) with genomics data, mortality data, and more to enhance data depth and completeness.
Data subscriptions that cover 22 tumor types and deliver a wide pool of clinical data sourced from the EHR, reflecting the patient journey from diagnosis onward.
Custom Data Solutions
Fit-for-purpose data curated to answer client-specific research questions through tailored cohorts and variables.
Integrated EHR-derived clinical data with comprehensive genomic profiling data for patients who are tested with a Foundation Medicine assay.
Imaging-Linked EHR Data
Datasets that link real-world radiology images with Flatiron’s EHR-derived clinical and outcomes data, enhancing evidence-generation.
Services for evidence and insights generation
Significant innovations in oncology RWD continue to advance the discipline of real-world evidence generation, and that’s why a deep and comprehensive understanding of data collection is essential.
Flatiron’s team of oncologists, biostatisticians, epidemiologists, and health outcomes researchers are each intimately familiar with oncology RWD. This enables Flatiron to offer end-to-end RWE solutions from study design to analysis, interpretation, and application of study results, providing the evidence and insights you need.
Clinical trial diversity planning
Our solution leverages data derived from diverse patient populations, at the point of care, offering actionable, accurate insight. No matter what stage you are in, Flatiron can help you design, or refine a trial diversity plan that addresses FDA guidelines.
Specialized tools and resources
Explore a variety of research questions with Flatiron’s interactive data visualization tool and analytics platform. Save and share cohorts for rapid collaboration across teams.
Flatiron Knowledge Center
Flatiron’s expansive knowledge repository includes tailored content based on your project and data product licenses including FAQs, analytic tutorials, training content, technical webinars, quality assurance documentation, release notes, data dictionaries, methodological guidance, and more.
Our suite of R Packages for statistical analysis and visualization enables faster, consistent evidence generation that’s scaled across your organization.
Learn how our customers are using Flatiron real-world evidence in oncology
Flatiron’s oncology real-world evidence solutions accelerate drug discovery by bridging the gap between genomics and clinical outcomes. Evaluating outcomes in specific populations improves the likelihood that you’ll discover the right drug targets in the right patient populations. Flatiron’s robust and trusted biomarker and treatment outcomes data are available for specific cancer types, including rare diseases, or across multiple tumors.
When the stakes are high, our biopharma partners use Flatiron’s oncology real-world evidence solutions, including fast insights, to support quick and impactful business decisions. Flatiron’s solutions can help you identify gaps and opportunities in your portfolio by gaining a deep understanding of the cancer landscape, in totality and by disease.
Flatiron’s oncology real-world evidence solutions accelerate and enhance clinical trial design, execution, and interpretation of results. Our industry experts and fit-for-purpose data improve your chances of generating the right RWE to support drug approval while maximizing efficiencies and cost-savings.
Submit your application with confidence when it matters the most by working with Flatiron. Our real-world data follows the highest regulatory-grade quality standards, and we have a long track record of partnering with leading biopharma companies to produce real-world evidence packages submitted to regulators in the U.S., Europe, and Asia.
As a pioneer in this space, Flatiron has partnered with the FDA, Duke-Margolis Health Policy Center, and others to advance data auditability, data depth, and endpoint validation.
Demonstrate your cancer drug’s value to payers and Health Technology Assessment (HTA) bodies with Flatiron’s oncology real-world evidence. Flatiron has both the expertise and the comprehensive data you need—whether evaluating health outcomes in specific patient cohorts or understanding treatment sequencing and testing patterns across tumor types.
Our extensive experience in HEOR and comparative effectiveness studies helps equip payers with the real-world evidence they need to make the best decisions, accelerating access to life-extending cancer treatments worldwide.